Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity

被引:7
|
作者
Gong, Grace Q. [1 ,2 ]
Kendall, Jackie D. [2 ,3 ]
Dickson, James M. J. [2 ,4 ]
Rewcastle, Gordon W. [2 ,3 ]
Buchanan, Christina M. [1 ,2 ]
Denny, William A. [2 ,3 ]
Shepherd, Peter R. [1 ,2 ,3 ]
Flanagan, Jack U. [2 ,3 ,5 ]
机构
[1] Univ Auckland, Dept Mol Med, Auckland, New Zealand
[2] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
[3] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[4] Univ Auckland, Sch Biol Sci, Auckland, New Zealand
[5] Univ Auckland, Dept Pharmacol & Clin Pharmacol, Auckland, New Zealand
关键词
PHOSPHOINOSITIDE 3-KINASE GAMMA; NONCONSERVED AMINO-ACIDS; KINASE ALPHA INHIBITORS; PROTEIN-LIGAND DOCKING; ISOFORM SELECTIVITY; STRUCTURAL BASIS; WATER-MOLECULES; CLINICAL-TRIALS; AKT ACTIVATION; BREAST-CANCER;
D O I
10.1042/BCJ20161098
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phosphoinositide 3-kinases (PI3Ks) are major regulators of many cellular functions, and hyperactivation of PI3K cell signalling pathways is a major target for anticancer drug discovery. PI3K alpha is the isoform most implicated in cancer, and our aim is to selectively inhibit this isoform, which may be more beneficial than concurrent inhibition of all Class I PI3Ks. We have used structure-guided design to merge high-selectivity and high-affinity characteristics found in existing compounds. Molecular docking, including the prediction of water-mediated interactions, was used to model interactions between the ligands and the PI3K alpha affinity pocket. Inhibition was tested using lipid kinase assays, and active compounds were tested for effects on PI3K cell signalling. The first-generation compounds synthesized had IC50 (half maximal inhibitory concentration) values >4 mu M for PI3K alpha yet were selective for PI3K alpha over the other Class I isoforms (beta, delta and gamma). The second-generation compounds explored were predicted to better engage the affinity pocket through direct and water-mediated interactions with the enzyme, and the IC50 values decreased by similar to 30-fold. Cell signalling analysis showed that some of the new PI3K alpha inhibitors were more active in the H1047R mutant bearing cell lines SK-OV-3 and T47D, compared with the E545K mutant harbouring MCF-7 cell line. In conclusion, we have used a structure-based design approach to combine features from two different compound classes to create new PI3K alpha-selective inhibitors. This provides new insights into the contribution of different chemical units and interactions with different parts of the active site to the selectivity and potency of PI3K alpha inhibitors.
引用
收藏
页码:2261 / 2276
页数:16
相关论文
共 50 条
  • [21] Novel inhibitors of the PI3K family
    Carnero, Amancio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (09) : 1265 - 1277
  • [22] Cardiovascular toxicity of PI3Kα inhibitors
    Sadasivan, Chandu
    Zhabyeyev, Pavel
    Labib, Dina
    White, James A.
    Paterson, D. Ian
    Oudit, Gavin Y.
    CLINICAL SCIENCE, 2020, 134 (19) : 2595 - 2622
  • [23] PI3Kα Inhibitors That Inhibit Metastasis
    Schmidt-Kittler, Oleg
    Zhu, Jiuxiang
    Yang, Jian
    Liu, Guosheng
    Hendricks, William
    Lengauer, Christoph
    Gabelli, Sandra B.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Huso, David L.
    Zhou, Shibin
    ONCOTARGET, 2010, 1 (05) : 339 - 348
  • [24] PI3K inhibitors in haematological malignancies
    Benjamin, David J.
    Prasad, Vinay
    LANCET ONCOLOGY, 2022, 23 (08): : E362 - E363
  • [25] The development of inhibitors of PI3K and Akt
    Dennis, PA
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [26] Clinical development of inhibitors of the PI3K
    Saura Manich, C.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR
    Ting Ran
    Tao Lu
    Haoliang Yuan
    Haichun Liu
    Jian Wang
    Weiwei Zhang
    Ying Leng
    Guowu Lin
    Shulin Zhuang
    Yadong Chen
    Journal of Molecular Modeling, 2012, 18 : 171 - 186
  • [28] A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR
    Ran, Ting
    Lu, Tao
    Yuan, Haoliang
    Liu, Haichun
    Wang, Jian
    Zhang, Weiwei
    Leng, Ying
    Lin, Guowu
    Zhuang, Shulin
    Chen, Yadong
    JOURNAL OF MOLECULAR MODELING, 2012, 18 (01) : 171 - 186
  • [29] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [30] Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates
    Mazzoletti, Marco
    Bortolin, Francesca
    Brunelli, Laura
    Pastorelli, Roberta
    Di Giandomenico, Silvana
    Erba, Eugenio
    Ubezio, Paolo
    Broggini, Massimo
    CANCER RESEARCH, 2011, 71 (13) : 4573 - 4584